Cost-outcome benefits of fibrate therapy in type 2 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 2, 2003, Pages 124-130

  Feher, Michael D ^a   Langley Hawthorne, Clare E ^b   Byrne, Christopher D ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b Health Economics Group   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Diabetes; Fibrate; Guidelines

Indexed keywords

ANTILIPEMIC AGENT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PROPHYLAXIS; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0042888781     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030020801     Document Type: Article

References (29)

1. Wilson PW, Kannel WB, Anderson KM. Lipids, glucose tolerance and vascular disease. The Framingham Study. Monogr Atheroscler 1985;13: 1-11.
2. Stamler J, Vaccaro O, Neaton JD et al. Diabetes and other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
3. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
4. Karlsson BW, Herlitz J, Hjalmarsson Å. Prognosis of acute myocardial infarction in diabetic and nondiabetic patients. Diabet Med 1993;10: 449-54.
5. Management of type 2 diabetes: Management of blood pressure and lipids. National Institute for Clinical Excellence. October 2002.
6. American Diabetes Association. Clinical practice recommendations 2001. Management of dyslipidemia in adults with diabetes. Diabetes Care 2001,24:S1-S133.
7. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. NICE 2001.
8. Rubins HB, Robins CJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1998;339:1349-57.
9. Sacks F, Pfeffer M, Moye L. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1995; 335:1001-09.
10. Robins S. Low HDL-C and coronary heart disease: the proper target for fibrate therapy. In HDL cholesterol: the missing link in cardiovascular risk reduction. Clinician 2000;18:14-17.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
12. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
13. British Heart Foundation Statistics Database 2000. British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford, 2000.
14. Monthly Index of Medical Specialities. Haymarket Medical Ltd. London.
15. Haffner SM, Asraf T. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents. Manag Care Interface 2000;13:52-8.
16. Perreault S, Hamilton VH, Lavoie F et al. A head-to-head comparison of the cost-effectiveness of HMG CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drug Ther 1997; 10:787-94.
17. Kirchgassler KU, Schiffner-Rohe J, Stahlheber U. Cost-effectiveness of micronized hyperlipidemia. Pharmacoeconomics 1997;12(2 Pt 2):237-46.
18. Guay DRP. Micronized fenofibrate: a new fibric acid hypolipidemia agent. Ann Pharmacother 1999,33:1083-103.
19. The Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention study, a randomised study. Lancet 2001;357:905-10.
20. Durrington PN, lllingworth DR. Lipid lowering drug therapy: more knowledge leads to more problems for composers of guidelines. Curr Opin Lipid 2000;11:345-9.
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
22. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin and cardiovascular disease. Arch Intern Med 2002;162:2597-604.
23. Steiner G. Lipid intervention trials in diabetes. Diabetes Care 2000;23 (suppl 2):B49-B53.
24. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel lll). JAMA 2001;285:2486-97.
25. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Atherosclerosis 1998;140:199-270.
26. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: a summary. BMJ 2000;320:705-08.
27. Currie CJ, Kraus D, Morgan CL et al. NHS acute sector expenditure for diabetes: the present, future and excess in-patient cost of care. Diabet Med 1997;14:686-92.
28. Too many too late: A report by Diabetes UK. June 2001. www.diabetes.org.uk
29. Colhoun HM, Dong W, Barakat MT, Mather HM, Poulter NR. The scope of cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-1994. Diabet Med 1999;16:35-40.